Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
Chemoresistance is the main challenge for the recurrent ovarian cancer therapy and responsible for treatment failure and unfavorable clinical outcome. Understanding mechanisms of chemoresistance in ovarian cancer would help to predict disease progression, develop new therapies and personalize systemic therapy. In the last decade, accumulating evidence demonstrates that epithelial-mesenchymal transition and cancer stem cells play important roles in ovarian cancer chemoresistance and metastasis. Treatment of epithelial-mesenchymal transition and cancer stem cells holds promise for improving current ovarian cancer therapies and prolonging the survival of recurrent ovarian cancer patients in the future. In this review, we focus on the role of epithelial-mesenchymal transition and cancer stem cells in ovarian cancer chemoresistance and explore the therapeutic implications for developing epithelial-mesenchymal transition and cancer stem cells associated therapies for future ovarian cancer treatment.
Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.|St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW, Australia.|Department of Gynecological Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China.|Zhengzhou University, Zhengzhou, Henan, China.
Junli
J
Deng
Department of Gynecological Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China.|Zhengzhou University, Zhengzhou, Henan, China.
Li
L
Wang
Department of Gynecological Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China.|Zhengzhou University, Zhengzhou, Henan, China.
Hongmin
H
Chen
Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.|St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW, Australia.
Jingli
J
Hao
Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.|St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW, Australia.
Jie
J
Ni
Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.|St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW, Australia.
Lei
L
Chang
School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia.
Wei
W
Duan
Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.|St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW, Australia.
Peter
P
Graham
Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.|St George and Sutherland Clinical School, University of New South Wales (UNSW), Kensington, NSW, Australia.
Yong
Y
Li
D000071916:AC133 Antigen / Q000032:analysis; D000444:Aldehyde Dehydrogenase / Q000032:analysis; D051927:CD24 Antigen; D019008:Drug Resistance, Neoplasm; D000071858:Epithelial Cell Adhesion Molecule / Q000032:analysis; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects*; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis; D014411:Neoplastic Stem Cells / Q000737:chemistry / Q000187:drug effects*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
D000071916:AC133 Antigen; D051927:CD24 Antigen; C497889:CD24 protein, human; C497483:CD44 protein, human; C499379:EPCAM protein, human; D000071858:Epithelial Cell Adhesion Molecule; D018960:Hyaluronan Receptors; C000606023:PROM1 protein, human; D000444:Aldehyde Dehydrogenase
CSC; EMT; chemoresistance; ovarian cancer; therapy